Bibliography
- Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25(11):2836-48
- Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-100
- Bohannon NJ, Ohannesian JP, Burdan AL, et al. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther 2000;22(9):1049-67
- Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26(9):1498-505
- Lombardo F, Salzano G, Messina MF, De Luca F. Compliance and administration methods in management of type 1 diabetes. Acta Biomed 2005;76(Suppl 3):66-9
- IMS Health. Estimated number of patients using FlexPen®, based on worldwide sales in number of packs sold, IMS world wide data Q4'07 and Daily Defined Dosage (DDD) for insulin as issued by WHO. 2007
- Asakura T, Seino H. Insulin dosing accuracy with FlexPen® versus syringe by healthcare professionals and healthy volunteers. Diabetes 2005;54(Suppl 1):A498-9
- Asakura T, Seino H, Kageyama M, Yohkoh N. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opinion 2008;24(5):1429-34
- Hänel H, Weise A, Sun W, et al. Differences in the dose accuracy of insulin pens. J Diabetes Sci Tech 2008;2(3):478-81
- Asakura T. Comparison of the dosing accuracy of two insulin injection devices. J Clin Res 2005;8:33-40
- Pfutzner A, Reimer T, Frokjaer LPF, Jorgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin 2008; 24(9):2545–9. Published online on 29 July 2008; doi:10.1185/03007990802329264
- Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 2004;27(10):2495-7
- Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004;26(4):531-40
- Asakura T, Seino H. A comparison of the usability of two types of disposable pen (FlexPen versus Humalog Kit) containing rapid-acting insulin analogues. Diabetes Metab 2003;29:S236
- Dreyer M. Comparison of metabolic control, safety, handling and patient acceptance of FlexPen with NovoLet in type 1 and type 2 diabetes patients. J Clin Res 2005;8:1-7
- Savas S, Koroglu BK, Koyuncuoglu HR, et al. The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients. Diabetes Res Clin Pract 2007;77(1):77-83
- Schady W, Abuaisha B, Boulton AJ. Observations on severe ulnar neuropathy in diabetes. J Diabetes Complications 1998;12(3):128-32
- Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabet Med 1993;10(Suppl 2):S82-6
- Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv 2007;4(2):165-74
- Rissler J, Jorgensen C, Rye Hansen M, Hansen N-A. Evaluation of injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother 2008;9(13):2217-22
- Phillips W, Lando H. Insulin confusion: an observation. Diabetes Care 2002;25(6):1103-4
- Adlersberg MA, Fernando S, Spollett GR, Inzucchi SE. Glargine and lispro: two cases of mistaken identity. Diabetes Care 2002;25(2):404-5
- Haak T, Edelman S, Walter C, et al. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther 2007;29(4):650-60
- Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data [Discussion 0-1]. Clin Ther 2006;28(10):1712-25
- Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29 Spec No:1294-305
- Asakura T, Seino H. Handling and safety of two insulin injection pens (FlexPen® and OptiClik®) in insulin-naive type 2 diabetes patients. Diabetes 2006;55(Suppl 1):A457